Colony stimulating factors (CSF) biosimilars. Progress?

Biosimilars are equivalent drugs for other biotechnological drugs for which patent has expired. These biopharmaceuticals are often looked upon as simple copies of parent drugs whose goal is solely to potentially generate costs savings. The expansion of available drugs is a subject of attention, crit...

Full description

Saved in:
Bibliographic Details
Published inTargeted oncology Vol. 7; no. Suppl 1; pp. 17 - 24
Main Authors Scotté, Florian, Launay-Vacher, Vincent, Rey, Jean-Baptiste
Format Journal Article
LanguageEnglish
Published Paris Springer-Verlag 01.03.2012
Springer Nature B.V
Subjects
Biological Products - therapeutic use
Biomedicine
Colony-Stimulating Factors - pharmacokinetics
Humans
Medicine
Medicine & Public Health
Oncology
Review
Therapeutic Equivalency
Tissue Distribution
Biosimilars
Supportive care
Epoietin
GCSF
Cancer
Online AccessGet full text
ISSN1776-2596
1776-260X
1776-260X
DOI10.1007/s11523-011-0189-2

Cover

More Information
Summary:Biosimilars are equivalent drugs for other biotechnological drugs for which patent has expired. These biopharmaceuticals are often looked upon as simple copies of parent drugs whose goal is solely to potentially generate costs savings. The expansion of available drugs is a subject of attention, criticism and quarrels, often related to a lack of product knowledge. These drugs are copies but need scientific development that must meet many strict rules. Many questions arise in connection with the marketing of several biosimilar drugs in the field of hematopoietic growth factors of white and red cells. Many of them should be discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1776-2596
1776-260X
1776-260X
DOI:10.1007/s11523-011-0189-2